Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.
Bakker DS, van der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM, Drylewicz J, Nierkens S, Boyman O, de Bruin-Weller MS, Thijs JL, van Wijk F. Bakker DS, et al. J Invest Dermatol. 2021 Aug;141(8):1943-1953.e13. doi: 10.1016/j.jid.2021.01.022. Epub 2021 Feb 18. J Invest Dermatol. 2021. PMID: 33610558 Free article.
Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy.
Ariëns LFM, Bakker DS, van der Schaft J, Garritsen FM, Thijs JL, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: bakker ds. Ther Adv Chronic Dis. 2018 May 11;9(9):159-170. doi: 10.1177/2040622318773686. eCollection 2018 Sep. Ther Adv Chronic Dis. 2018. PMID: 30181845 Free PMC article. Review.
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: bakker ds. Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31. Allergy. 2020. PMID: 31593343
Dupilumab facial redness: Positive effect of itraconazole.
de Beer FSA, Bakker DS, Haeck I, Ariens L, van der Schaft J, van Dijk MR, de Bruin-Weller MS. de Beer FSA, et al. Among authors: bakker ds. JAAD Case Rep. 2019 Oct 22;5(10):888-891. doi: 10.1016/j.jdcr.2019.07.020. eCollection 2019 Oct. JAAD Case Rep. 2019. PMID: 31681828 Free PMC article. No abstract available.
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Spekhorst LS, Ariëns LFM, van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ, de Ridder I, Sloeserwij A, Romeijn GLE, de Graaf M, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Spekhorst LS, et al. Among authors: bakker ds. Allergy. 2020 Sep;75(9):2376-2379. doi: 10.1111/all.14324. Epub 2020 May 5. Allergy. 2020. PMID: 32302412 Free PMC article. No abstract available.
Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers.
Bakker DS, Nierkens S, Knol EF, Giovannone B, Delemarre EM, van der Schaft J, van Wijk F, de Bruin-Weller MS, Drylewicz J, Thijs JL. Bakker DS, et al. J Allergy Clin Immunol. 2021 Jan;147(1):189-198. doi: 10.1016/j.jaci.2020.04.062. Epub 2020 Jun 8. J Allergy Clin Immunol. 2021. PMID: 32526312 Free article.
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, Kamsteeg M, Voorberg AN, Oosting AJ, de Ridder I, Sloeserwij A, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: bakker ds. J Am Acad Dermatol. 2021 Apr;84(4):1000-1009. doi: 10.1016/j.jaad.2020.08.127. Epub 2020 Sep 16. J Am Acad Dermatol. 2021. PMID: 32946967
36 results